SEC Form 4 · accession 0001209191-17-034450
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Moze
Officer — EVP, Chief Admin. Officer
Period of report
May 19, 2017
Accepted (ET)
May 22, 2017 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | May 19, 2017 | M | 16,075 | — | A | 69,944 | D | |
| Ordinary Shares | May 19, 2017 | F | 7,347 | $10.50 | D | 62,597 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | May 19, 2017 | M | 16,075 | D | — | — | Ordinary Shares | 16,075 | 16,075 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2The restricted stock units vest in four annual installments of 16,075 shares, on each anniversary of the vesting commencement date (May 19, 2014).